CELL-FREE DNA TESTING IN PRENATAL SCREENING FOR CHROMOSOMAL DISORDERS: DIAGNOSTIC PERFORMANCE, BIOLOGICAL LIMITS AND INTERPRETATION OF RESULTS
Scientific and Innovative Therapy · 2026 · 4 (5) · 122-137
DOI: 10.64582/ivit.uz.1212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific and Innovative Therapy, 2026. Verfasst von Gulnora Shamuratova. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate, on the basis of current evidence, the diagnostic performance of maternal cell-free DNA (cfDNA) testing in prenatal screening for chromosomal disorders, its biological and statistical limits, and the conditions for correct interpretation of positive and negative results. Material and methods. A systematic search of publications issued between 1997 and 2025 was performed in PubMed/MEDLINE, Scopus, Web of Science and the Cochrane Library. Meta-analyses, large prospective multicentre studies, comparative studies of chromosomal microarray analysis and international guidelines (ACOG, ACMG) were included. Selection followed PRISMA principles. The positive predictive value (PPV) was additionally calculated using Bayes' theorem for a range of prevalence levels.
Results
According to meta-analysis, cfDNA testing detects trisomy 21 with 99.7 % sensitivity and a 0.04 % false-positive rate. In a general population of 15,841 pregnant women, the PPV for trisomy 21 was 80.9 % for cfDNA testing and 3.4 % for standard screening. However, PPV is a property of the population rather than the test: the calculated PPV for trisomy 21 is 33.3 % at a prevalence of 1:5000 and 96.2 % at 1:100; for monosomy X it falls to 40.7 % at 1:1000, and the observed PPV for 22q11.2 deletion was 23.7 %. Feto-placental mosaicism, occult maternal tumours and test failure are the main sources of discordant results. With a normal karyotype, chromosomal microarray analysis detected additional pathogenic copy-number variants in 6.0 % of fetuses with ultrasound anomalies and in 1.7 % of those without. Conclusion. cfDNA testing is the most accurate screening method for the common trisomies but is not a diagnostic test: a positive result must be confirmed by invasive testing, and a negative result does not mean a normal fetal karyotype. When ultrasound reveals an anomaly, invasive diagnosis with microarray analysis rather than cfDNA testing is indicated. Pre- and post-test genetic counselling is a mandatory condition for correct interpretation.
Zitieren
APA
Shamuratova, G. (2026). CELL-FREE DNA TESTING IN PRENATAL SCREENING FOR CHROMOSOMAL DISORDERS: DIAGNOSTIC PERFORMANCE, BIOLOGICAL LIMITS AND INTERPRETATION OF RESULTS. Scientific and Innovative Therapy, 4(5), 122-137. https://doi.org/10.64582/ivit.uz.1212
Vancouver
Shamuratova G. CELL-FREE DNA TESTING IN PRENATAL SCREENING FOR CHROMOSOMAL DISORDERS: DIAGNOSTIC PERFORMANCE, BIOLOGICAL LIMITS AND INTERPRETATION OF RESULTS. Scientific and Innovative Therapy. 2026;4(5):122-137. doi:10.64582/ivit.uz.1212
BibTeX
@article{Shamuratova2026,
author = {Shamuratova, Gulnora},
title = {CELL-FREE DNA TESTING IN PRENATAL SCREENING FOR CHROMOSOMAL DISORDERS: DIAGNOSTIC PERFORMANCE, BIOLOGICAL LIMITS AND INTERPRETATION OF RESULTS},
journal = {Scientific and Innovative Therapy},
year = {2026},
volume = {4},
number = {5},
pages = {122--137},
doi = {10.64582/ivit.uz.1212}
}
EUVIMED